Background There is a growing need for information regarding the recent coronavirus disease MESHD of 2019 (Covid-19). We present a comprehensive report of Covid-19 patients in Iran.Methods One hundred hospitalized patients with Covid-19 were studied. Data on potential source of exposure, demographic, clinical, and paraclinical features, therapy outcome, and post-discharge follow-up were analyzed.Results The median age TRANS of the patients was 58 years, and the majority of the patients (72.7%) were above 50 years of age TRANS. Fever MESHD Fever HP was present in 45.2% of the patients on admission. The most common clinical symptoms were shortness of breath (74%) and cough MESHD cough HP (68%). Most patients had elevated C-reactive protein (92.3%), elevated erythrocyte sedimentation rate HP (82.9%), lymphocytopenia (74.2 %) on admission. Lower lobes of the lung were most commonly involved, and ground-glass opacity (81.8%) was the most frequent finding in CT scans. The administration of hydroxychloroquine improved the clinical outcome of the patients. Lopinavir/ritonavir was efficacious at younger ages TRANS. Of the 70 discharged patients, 40% had symptom relapse, (8.6%) were readmitted to the hospital, and 3 patients (4.3%) died.Conclusions This report demonstrates a heterogeneous nature of clinical manifestations in patients affected with Covid-19. The most common presenting symptoms are non-specific, so attention should be made on broader testing, especially in age groups TRANS with the greatest risk and younger individuals who can serve as carriers TRANS of the disease MESHD. Hydroxychloroquine and lopinavir/ritonavir (in younger age group TRANS) can be potential treatment options. Finally, patients discharged from the hospital should be followed up because of potential symptom relapse.